{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-003291","form_type":"8-K","ticker":"BEAM","cik":"0001745999","company_name":"Beam Therapeutics Inc.","filed_at":"2021-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.921890+00:00","generated_at":"2026-06-28T11:39:11.699414+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Beam gets FDA clearance for first base editing IND (BEAM-101); Q3 net loss $28.1M, cash $933.4M","bullets":["FDA cleared IND for BEAM-101 (sickle cell disease); first open IND for base editing.","Beam initiated IND-enabling studies for BEAM-102 (Makassar base editing for sickle cell).","Q3 net loss $28.1M ($0.42/share); R&D $54.6M, G&A $15.8M.","Cash, equivalents & securities $933.4M as of Sep 30, 2021, up from $299.7M at Dec 31, 2020.","Non-exclusive license to Sana for Cas12b for $50M upfront; potential milestones/royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-003291","json":"https://secwatch.observer/filing/0000950170-21-003291.json","markdown":"https://secwatch.observer/filing/0000950170-21-003291.md","text":"https://secwatch.observer/filing/0000950170-21-003291.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1745999/000095017021003291/0000950170-21-003291-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1745999/000095017021003291/beam-20211105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T11:39:11.699414+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9c02948a2b","claim":"John Maraganore was elected as Director at Beam Therapeutics Inc..","evidence_excerpt":"On November 5, 2021, the Board of Directors (the “Board”) of the Company, upon recommendation from the Nominating and Corporate Governance Committee of the Board, expanded the size of the Board from six to seven members and elected John Maraganore, Ph.D., as a member of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1745999/000095017021003291/0000950170-21-003291-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}